Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Hypertension Reports
Erschienen in: Current Hypertension Reports 8/2017

01.08.2017 | Hypertension and Metabolic Syndrome (J Sperati, Section Editor)

Molecular Mechanisms of Sodium-Sensitive Hypertension in the Metabolic Syndrome

verfasst von: Jonathan M. Nizar, Vivek Bhalla

Erschienen in: Current Hypertension Reports | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

We review the known mechanisms of sodium-sensitive hypertension in the metabolic syndrome with a focus on preclinical models, differences between these models, and methodological limitations. We also identify future directions for a better understanding and treatment of this common condition.

Recent Findings

Rigorous methodologies to measure blood pressure in preclinical models may clarify some of the inconsistencies in the literature. Renal, neural, hormonal, and cardiovascular systems are dysregulated and contribute to elevated blood pressure. Local renin-angiotensin systems enhance systemic hormone signaling to increase blood pressure.

Summary

Since the original description of metabolic syndrome, investigators from many fields have contributed to an increasingly complex and mechanistic understanding of this common condition. These systems integrate to regulate sodium transport in the kidney leading to hypertension and enhanced sodium sensitivity. An array of non-uniform preclinical models are used and support clinical studies to inform which models are pathophysiologically relevant for further mechanistic studies to guide targeted therapy.
Literatur
1.
Alberti KG, Zimmet P, Shaw J, Group IDFETFC. The metabolic syndrome-a new worldwide definition. Lancet. 2005;366(9491):1059–62.CrossRef
2.
Haller H. Epidermiology and associated risk factors of hyperlipoproteinemia. Z Gesamte Inn Med. 1977;32(8):124–8.PubMed
3.
Joslin E. The prevention of diabetes mellitus. JAMA. 1921;76:79–84.CrossRef
4.
Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–607.PubMedCrossRef
5.
Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care. 2004;27(10):2444–9.PubMedCrossRef
6.
Kawasaki T, Delea CS, Bartter FC, Smith H. The effect of high-sodium and low-sodium intakes on blood pressure and other related variables in human subjects with idiopathic hypertension. Am J Med. 1978;64(2):193–8.PubMedCrossRef
7.
8.
Dyer AR, Elliott P, Shipley M. Body mass index versus height and weight in relation to blood pressure. Findings for the 10,079 persons in the INTERSALT Study. Am J Epidemiol. 1990;131(4):589–96.PubMedCrossRef
9.
Garrison RJ, Kannel WB, Stokes J 3rd, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med. 1987;16(2):235–51.PubMedCrossRef
10.
Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, Smith West D, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med. 2001;134(1):1–11.PubMedCrossRef
11.
Zavaroni I, Mazza S, Dall’Aglio E, Gasparini P, Passeri M, Reaven GM. Prevalence of hyperinsulinaemia in patients with high blood pressure. J Intern Med 1992;231(3):235–240.
12.
Dyer AR, Elliott P, Shipley M, Stamler R, Stamler J. Body mass index and associations of sodium and potassium with blood pressure in INTERSALT. Hypertension. 1994;23(6 Pt 1):729–36.PubMedCrossRef
13.
Guyton AC. Kidneys and fluids in pressure regulation. Small volume but large pressure changes. Hypertension. 1992;19(1 Suppl):I2–8.PubMedCrossRef
14.
Mancia G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens. 2007;25(5):909–20.PubMedCrossRef
15.
Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens. 2001;14(6 Pt 2):103S–15S.PubMedCrossRef
16.
Dobrian AD, Davies MJ, Schriver SD, Lauterio TJ, Prewitt RL. Oxidative stress in a rat model of obesity-induced hypertension. Hypertension. 2001;37(2 Pt 2):554–60.PubMedCrossRef
17.
Quigley JE, Elmarakby AA, Knight SF, Manhiani MM, Stepp DW, Olearzcyk JJ, et al. Obesity induced renal oxidative stress contributes to renal injury in salt-sensitive hypertension. Clin Exp Pharmacol Physiol. 2009;36(7):724–8.PubMedPubMedCentralCrossRef
18.
Chung S, Park CW, Shin SJ, Lim JH, Chung HW, Youn DY, et al. Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats. Nephrol Dial Transplant. 2010;25(2):389–99.PubMedCrossRef
19.
Catena C, Cavarape A, Novello M, Giacchetti G, Sechi LA. Insulin receptors and renal sodium handling in hypertensive fructose-fed rats. Kidney Int. 2003;64(6):2163–71.PubMedCrossRef
20.
Endre T, Mattiasson I, Berglund G, Hulthn UL. Insulin and renal sodium retention in hypertension-prone men. Hypertension. 1994;23(3):313–9.PubMedCrossRef
21.
Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, et al. Insulin resistance in essential hypertension. N Engl J Med. 1987;317(6):350–7.PubMedCrossRef
22.
Skott P, Vaag A, Bruun NE, Hother-Nielsen O, Gall MA, Beck-Nielsen H, et al. Effect of insulin on renal sodium handling in hyperinsulinaemic type 2 (non-insulin-dependent) diabetic patients with peripheral insulin resistance. Diabetologia. 1991;34(4):275–81.PubMedCrossRef
23.
Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A. 2003;100(24):14,211–6.CrossRef
24.
Kenyon CJ. Mineralocorticoid-induced hypertension in obese Zucker rats. J Hypertens. 2002;20(11):2151–2.PubMedCrossRef
25.
26.
Nishida H, Sohara E, Nomura N, Chiga M, Alessi DR, Rai T, et al. Phosphatidylinositol 3-kinase/Akt signaling pathway activates the WNK-OSR1/SPAK-NCC phosphorylation cascade in hyperinsulinemic db/db mice. Hypertension. 2012;60(4):981–90.PubMedPubMedCentralCrossRef
27.
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.PubMedCrossRef
28.
DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14(3):173–94.PubMedCrossRef
29.
Lima NK, Abbasi F, Lamendola C, Reaven GM. Prevalence of insulin resistance and related risk factors for cardiovascular disease in patients with essential hypertension. Am J Hypertens. 2009;22(1):106–11.PubMedCrossRef
30.
Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes. 1998;47(5):699–713.PubMedCrossRef
31.
Nizar JM, Dong W, McClellan RB, Labarca M, Zhou Y, Wong J, et al. Sodium-sensitive elevation in blood pressure is ENaC independent in diet-induced obesity and insulin resistance. Am J Physiol Renal Physiol. 2016;310(9):F812-20.
32.
Kanarek RB, Orthen-Gambill N. Differential effects of sucrose, fructose and glucose on carbohydrate-induced obesity in rats. J Nutr. 1982;112(8):1546–54.PubMed
33.
Mills E, Kuhn CM, Feinglos MN, Surwit R. Hypertension in CB57BL/6J mouse model of non-insulin-dependent diabetes mellitus. Am J Physiol. 1993;264(1 Pt 2):R73–8.PubMed
34.
Mark AL, Shaffer RA, Correia ML, Morgan DA, Sigmund CD, Haynes WG. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. J Hypertens. 1999;17(12 Pt 2):1949–53.PubMedCrossRef
35.
Mozaffari MS, Abdelsayed R, Liu JY, Zakhary I, Baban B. Renal distal tubule proliferation and increased aquaporin 2 level but decreased urine osmolality in db/db mouse: treatment with chromium picolinate. Exp Mol Pathol. 2012;92(1):54–8.PubMedCrossRef
36.
Hartner A, Cordasic N, Klanke B, Veelken R, Hilgers KF. Strain differences in the development of hypertension and glomerular lesions induced by deoxycorticosterone acetate salt in mice. Nephrol Dial Transpl. 2003;18(10):1999–2004.CrossRef
37.
Matsushita T, Miyahara Y, Matsushita M, Yakabe K, Yamaguchi K, Furukawa K, et al. Liddle’s syndrome in an elderly woman. Intern Med. 1998;37(4):391–5.PubMedCrossRef
38.
Pradervand S, Wang Q, Burnier M, Beermann F, Horisberger JD, Hummler E, et al. A mouse model for Liddle’s syndrome. J Am Soc Nephrol: JASN. 1999;10(12):2527–33.PubMed
39.
Achard JM, Disse-Nicodeme S, Fiquet-Kempf B, Jeunemaitre X. Phenotypic and genetic heterogeneity of familial hyperkalaemic hypertension (Gordon syndrome). Clin Exp Pharmacol Physiol. 2001;28(12):1048–52.PubMedCrossRef
40.
Lalioti MD, Zhang J, Volkman HM, Kahle KT, Hoffmann KE, Toka HR, et al. Wnk4 controls blood pressure and potassium homeostasis via regulation of mass and activity of the distal convoluted tubule. Nat Genet. 2006;38(10):1124–32.PubMedCrossRef
41.
Huang DY, Boini KM, Osswald H, Friedrich B, Artunc F, Ullrich S, et al. Resistance of mice lacking the serum- and glucocorticoid-inducible kinase SGK1 against salt-sensitive hypertension induced by a high-fat diet. Am J Physiol Renal Physiol. 2006;291(6):F1264–73.PubMedCrossRef
42.
Kennedy AJ, Ellacott KL, King VL, Hasty AH. Mouse models of the metabolic syndrome. Dis Model Mech. 2010;3(3–4):156–66.
43.
Deji N, Kume S, Araki S, Isshiki K, Araki H, Chin-Kanasaki M, et al. Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension. Biochem Biophys Res Commun. 2012;418(3):559–64.PubMedCrossRef
44.
Deji N, Kume S, Araki S, Soumura M, Sugimoto T, Isshiki K, et al. Structural and functional changes in the kidneys of high-fat diet-induced obese mice. Am J Physiol Renal Physiol. 2009;296(1):F118–26.PubMedCrossRef
45.
Lautz J, Kessler H, Blaney JM, Scheek RM, Van Gunsteren WF. Calculating three-dimensional molecular structure from atom-atom distance information: cyclosporin A. Int J Pept Protein Res. 1989;33(4):281–8.PubMedCrossRef
46.
Symons JD, McMillin SL, Riehle C, Tanner J, Palionyte M, Hillas E, et al. Contribution of insulin and Akt1 signaling to endothelial nitric oxide synthase in the regulation of endothelial function and blood pressure. Circ Res. 2009;104(9):1085–94.PubMedPubMedCentralCrossRef
47.
Purkayastha S, Zhang G, Cai D. Uncoupling the mechanisms of obesity and hypertension by targeting hypothalamic IKK-beta and NF-kappaB. Nat Med. 2011;17(7):883–7.PubMedPubMedCentralCrossRef
48.
Komers R, Rogers S, Oyama TT, Xu B, Yang CL, McCormick J, et al. Enhanced phosphorylation of Na(+)-Cl- co-transporter in experimental metabolic syndrome: role of insulin. Clin Sci (Lond). 2012;123(11):635–47.PubMedPubMedCentralCrossRef
49.
Williams TD, Chambers JB, Roberts LM, Henderson RP, Overton JM. Diet-induced obesity and cardiovascular regulation in C57BL/6J mice. Clin Exp Pharmacol Physiol. 2003;30(10):769–78.PubMedCrossRef
50.
Rahmouni K, Morgan DA, Morgan GM, Mark AL, Haynes WG. Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes. 2005;54(7):2012–8.PubMedCrossRef
51.
Huang DY, Boini KM, Friedrich B, Metzger M, Just L, Osswald H, et al. Blunted hypertensive effect of combined fructose and high-salt diet in gene-targeted mice lacking functional serum- and glucocorticoid-inducible kinase SGK1. Am J Physiol Regul Integr Comp Physiol. 2006;290(4):R935–44.PubMedCrossRef
52.
Roncon-Albuquerque R, Jr., Moreira-Rodrigues M, Faria B, Ferreira AP, Cerqueira C, Lourenco AP, et al. Attenuation of the cardiovascular and metabolic complications of obesity in CD14 knockout mice. Life Sci. 2008;83(13–14):502–10.
53.
Gupte M, Boustany-Kari CM, Bharadwaj K, Police S, Thatcher S, Gong MC, et al. ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet. Am J Physiol Regul Integr Comp Physiol. 2008;295(3):R781–8.PubMedPubMedCentralCrossRef
54.
Rong X, Li Y, Ebihara K, Zhao M, Naowaboot J, Kusakabe T, et al. Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice. Diabetologia. 2010;53(8):1727–31.PubMedCrossRef
55.
Belin de Chantemele EJ, Mintz JD, Rainey WE, Stepp DW. Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice. Hypertension. 2011;58(2):271–9.PubMedPubMedCentralCrossRef
56.
Costa MV, Fernandes-Santos C, Faria Tda S, Aguila MB, Mandarim-de-Lacerda CA. Diets rich in saturated fat and/or salt differentially modulate atrial natriuretic peptide and renin expression in C57BL/6 mice. Eur J Nutr. 2012;51(1):89–96.PubMedCrossRef
57.
Mingorance C, Duluc L, Chalopin M, Simard G, Ducluzeau PH, Herrera MD, et al. Propionyl-L-carnitine corrects metabolic and cardiovascular alterations in diet-induced obese mice and improves liver respiratory chain activity. PloS One. 2012;7(3):e34268.PubMedPubMedCentralCrossRef
58.
Marshall NJ, Liang L, Bodkin J, Dessapt-Baradez C, Nandi M, Collot-Teixeira S, et al. A role for TRPV1 in influencing the onset of cardiovascular disease in obesity. Hypertension. 2013;61(1):246–52.PubMedCrossRef
59.
Inoue E, Ichiki T, Takeda K, Matsuura H, Hashimoto T, Ikeda J, et al. Beraprost sodium, a stable prostacyclin analogue, improves insulin resistance in high-fat diet-induced obese mice. J Endocrinol. 2012;213(3):285–91.PubMedCrossRef
60.
Gamliel-Lazarovich A, Raz-Pasteur A, Coleman R, Keidar S. The effects of aldosterone on diet-induced fatty liver formation in male C57BL/6 mice: comparison of adrenalectomy and mineralocorticoid receptor blocker. Eur J Gastroenterol Hepatol. 2013;25(9):1086–92.PubMedCrossRef
61.
Van Vliet BN, McGuire J, Chafe L, Leonard A, Joshi A, Montani JP. Phenotyping the level of blood pressure by telemetry in mice. Clin Exp Pharmacol Physiol. 2006;33(11):1007–15.PubMedCrossRef
62.
Van Vliet BN, Chafe LL, Montani JP. Characteristics of 24 h telemetered blood pressure in eNOS-knockout and C57Bl/6J control mice. J Physiol. 2003;549(Pt 1):313–25.PubMedPubMedCentralCrossRef
63.
Feng M, Whitesall S, Zhang Y, Beibel M, D’Alecy L, DiPetrillo K. Validation of volume-pressure recording tail-cuff blood pressure measurements. Am J Hypertens 2008;21(12):1288–1291.
64.
Kubota Y, Umegaki K, Kagota S, Tanaka N, Nakamura K, Kunitomo M, et al. Evaluation of blood pressure measured by tail-cuff methods (without heating) in spontaneously hypertensive rats. Biol Pharm Bull. 2006;29(8):1756–8.PubMedCrossRef
65.
Plehm R, Barbosa ME, Bader M. Animal models for hypertension/blood pressure recording. Methods Mol Med. 2006;129:115–26.PubMed
66.
Zhao X, Ho D, Gao S, Hong C, Vatner DE, Vatner SF. Arterial pressure monitoring in mice. Curr Protoc Mouse Biol. 2011;1:105–22.PubMedPubMedCentral
67.
Yun CC. Concerted roles of SGK1 and the Na+/H+ exchanger regulatory factor 2 (NHERF2) in regulation of NHE3. Cell Physiol Biochem. 2003;13(1):29–40.
68.
Faresse N, Lagnaz D, Debonneville A, Ismailji A, Maillard M, Fejes-Toth G, et al. Inducible kidney-specific Sgk1 knockout mice show a salt-losing phenotype. Am J Physiol Ren Physiol. 2012;302(8):F977–85.CrossRef
69.
Lang F, Bohmer C, Palmada M, Seebohm G, Strutz-Seebohm N, Vallon V. (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms. Physiol Rev. 2006;86(4):1151–78.PubMedCrossRef
70.
Zheng Y, Yamada H, Sakamoto K, Horita S, Kunimi M, Endo Y, et al. Roles of insulin receptor substrates in insulin-induced stimulation of renal proximal bicarbonate absorption. J Am Soc Nephrol. 2005;16(8):2288–95.PubMedCrossRef
71.
Davies M, Fraser SA, Galic S, Choy SW, Katerelos M, Gleich K, et al. Novel mechanisms of Na + retention in obesity: phosphorylation of NKCC2 and regulation of SPAK/OSR1 by AMPK. Am J Physiol Ren Physiol. 2014;307(1):F96–F106.CrossRef
72.
Song J, Hu X, Riazi S, Tiwari S, Wade JB, Ecelbarger CA. Regulation of blood pressure, the epithelial sodium channel (ENaC), and other key renal sodium transporters by chronic insulin infusion in rats. Am J Physiol Ren Physiol. 2006;290(5):F1055–64.CrossRef
73.
Sowers JR, Whitfield LA, Catania RA, Stern N, Tuck ML, Dornfeld L, et al. Role of the sympathetic nervous system in blood pressure maintenance in obesity. J Clin Endocrinol Metab. 1982;54(6):1181–6.PubMedCrossRef
74.
Wofford MR, Anderson DC Jr, Brown CA, Jones DW, Miller ME, Hall JE. Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens. 2001;14(7 Pt 1):694–8.PubMedCrossRef
75.
Asirvatham-Jeyaraj N, Fiege JK, Han R, Foss J, Banek CT, Burbach BJ, et al. Renal denervation normalizes arterial pressure with no effect on glucose metabolism or renal inflammation in obese hypertensive mice. Hypertension. 2016;68(4):929–36.PubMedCrossRef
76.
Alonso-Galicia M, Brands MW, Zappe DH, Hall JE. Hypertension in obese Zucker rats. Role of angiotensin II and adrenergic activity. Hypertension. 1996;28(6):1047–54.PubMedCrossRef
77.
Rocchini AP, Moorehead CP, DeRemer S, Bondie D. Pathogenesis of weight-related changes in blood pressure in dogs. Hypertension. 1989;13(6 Pt 2):922–8.PubMedCrossRef
78.
Rocchini AP, Mao HZ, Babu K, Marker P, Rocchini AJ. Clonidine prevents insulin resistance and hypertension in obese dogs. Hypertension. 1999;33(1 Pt 2):548–53.PubMedCrossRef
79.
Mark AL, Correia ML, Rahmouni K, Haynes WG. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J Hypertens. 2002;20(7):1245–50.PubMedCrossRef
80.
do Carmo JM, da Silva AA, Cai Z, Lin S, Dubinion JH, Hall JE. Control of blood pressure, appetite, and glucose by leptin in mice lacking leptin receptors in proopiomelanocortin neurons. Hypertension. 2011;57(5):918–26.PubMedPubMedCentralCrossRef
81.
Rahmouni K, Haynes WG, Morgan DA, Mark AL. Role of melanocortin-4 receptors in mediating renal sympathoactivation to leptin and insulin. J Neurosci. 2003;23(14):5998–6004.PubMed
82.
Brito MN, Brito NA, Baro DJ, Song CK, Bartness TJ. Differential activation of the sympathetic innervation of adipose tissues by melanocortin receptor stimulation. Endocrinology. 2007;148(11):5339–47.PubMedCrossRef
83.
Greenfield JR, Miller JW, Keogh JM, Henning E, Satterwhite JH, Cameron GS, et al. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med. 2009;360(1):44–52.PubMedCrossRef
84.
Haynes WG, Morgan DA, Djalali A, Sivitz WI, Mark AL. Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension. 1999;33(1 Pt 2):542–7.PubMedCrossRef
85.
da Silva AA, Kuo JJ, Hall JE. Role of hypothalamic melanocortin 3/4-receptors in mediating chronic cardiovascular, renal, and metabolic actions of leptin. Hypertension. 2004;43(6):1312–7.PubMedCrossRef
86.
da Silva AA, do Carmo JM, Kanyicska B, Dubinion J, Brandon E, Hall JE. Endogenous melanocortin system activity contributes to the elevated arterial pressure in spontaneously hypertensive rats. Hypertension. 2008;51(4):884–90.PubMedPubMedCentralCrossRef
87.
Tallam LS, Stec DE, Willis MA, da Silva AA, Hall JE. Melanocortin-4 receptor-deficient mice are not hypertensive or salt-sensitive despite obesity, hyperinsulinemia, and hyperleptinemia. Hypertension. 2005;46(2):326–32.PubMedCrossRef
88.
Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell. 1997;88(1):131–41.PubMedCrossRef
89.
Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O’Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 2003;348(12):1085–1095.
90.
Kassab S, Kato T, Wilkins FC, Chen R, Hall JE, Granger JP. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension. 1995;25(4):893–7.PubMedCrossRef
91.
Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370(15):1393–1401.
92.
Healy V, Thompson C, Johns EJ. The adrenergic regulation of proximal tubular Na(+)/H(+) exchanger 3 in the rat. Acta Physiol (Oxf). 2014;210(3):678–89.CrossRef
93.
DiBona GF, Sawin LL. Effect of renal nerve stimulation on NaCl and H2O transport in Henle’s loop of the rat. Am J Physiol. 1982;243(6):F576–80.PubMed
94.
Chan YL. Adrenergic control of bicarbonate absorption in the proximal convoluted tubule of the rat kidney. Pflugers Arch. 1980;388(2):159–64.PubMedCrossRef
95.
DiBona GF. Neural regulation of renal tubular sodium reabsorption and renin secretion. Fed Proc. 1985;44(13):2816–22.PubMed
96.
Thomson SC, Vallon V. Alpha 2-adrenoceptors determine the response to nitric oxide inhibition in the rat glomerulus and proximal tubule. J Am Soc Nephrol. 1995;6(5):1482–90.PubMed
97.
Quan A, Baum M. The renal nerve is required for regulation of proximal tubule transport by intraluminally produced ANG II. Am J Physiol Ren Physiol. 2001;280(3):F524–9.
98.
Terker AS, Yang CL, McCormick JA, Meermeier NP, Rogers SL, Grossmann S, et al. Sympathetic stimulation of thiazide-sensitive sodium chloride cotransport in the generation of salt-sensitive hypertension. Hypertension. 2014;64(1):178–84.PubMedPubMedCentralCrossRef
99.
Ramseyer VD, Ortiz PA, Carretero OA, Garvin JL. Angiotensin II-mediated hypertension impairs nitric oxide-induced NKCC2 inhibition in thick ascending limbs. Am J Physiol Ren Physiol. 2016;310(8):F748–F54.
100.
Richardson C, Alessi DR. The regulation of salt transport and blood pressure by the WNK-SPAK/OSR1 signaling pathway. J Cell Sci. 2008;121(Pt 20):3293–304.PubMedCrossRef
101.
Loperena R, Harrison DG. Oxidative stress and hypertensive diseases. Med Clin North Am. 2017;101(1):169–93.PubMedCrossRef
102.
Wenzel U, Turner JE, Krebs C, Kurts C, Harrison DG, Ehmke H. Immune mechanisms in arterial hypertension. J Am Soc Nephrol. 2016;27(3):677–86.PubMedCrossRef
103.
Huh JY, Park YJ, Ham M, Kim JB. Crosstalk between adipocytes and immune cells in adipose tissue inflammation and metabolic dysregulation in obesity. Mol Cells. 2014;37(5):365–71.PubMedPubMedCentralCrossRef
104.
Bickel CA, Verbalis JG, Knepper MA, Ecelbarger CA. Increased renal Na-K-ATPase, NCC, and beta-ENaC abundance in obese Zucker rats. Am J Physiol Ren Physiol. 2001;281(4):F639–48.
105.
Manhiani MM, Cormican MT, Brands MW. Chronic sodium-retaining action of insulin in diabetic dogs. Am J Physiol Renal Physiol. 2011;300(4):F957–65.PubMedPubMedCentralCrossRef
106.
DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Inv. 1975;55(4):845–55.CrossRef
107.
Airaksinen J, Lahtela JT, Ikaheimo MJ, Sotaniemi EA, Takkunen JT. Intravenous insulin has no effect on myocardial contractility or heart rate in healthy subjects. Diabetologia. 1985;28(9):649–52.PubMedCrossRef
108.
Gotzsche PC, Kelbaek H, Vissing SF, Nielsen SL, Munck O, Christensen NJ, et al. Acute cardiovascular effects of insulin in hyperglycaemic type I diabetics. Scand J Clin Lab Invest. 1991;51(1):93–7.PubMed
109.
Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Inv. 1991;87(6):2246–52.CrossRef
110.
Li L, Garikepati RM, Tsukerman S, Tiwari S, Ecelbarger CM. Salt sensitivity of nitric oxide generation and blood pressure in mice with targeted knockout of the insulin receptor from the renal tubule. Am J Physiol Regul Integr Comp Physiol. 2012;303(5):R505–12.PubMedPubMedCentralCrossRef
111.
Tiwari S, Sharma N, Gill PS, Igarashi P, Kahn CR, Wade JB, et al. Impaired sodium excretion and increased blood pressure in mice with targeted deletion of renal epithelial insulin receptor. Proc Natl Acad Sci U S A. 2008;105(17):6469–74.PubMedPubMedCentralCrossRef
112.
Traykova-Brauch M, Schonig K, Greiner O, Miloud T, Jauch A, Bode M, et al. An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nat Med. 2008;14(9):979–84.PubMedPubMedCentralCrossRef
113.
Yiannikouris F, Gupte M, Putnam K, Thatcher S, Charnigo R, Rateri DL, et al. Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice. Hypertension. 2012;60(6):1524–30.PubMedPubMedCentralCrossRef
114.
Massiera F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM, et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J. 2001;15(14):2727–9.PubMed
115.
Harte A, McTernan P, Chetty R, Coppack S, Katz J, Smith S, et al. Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation. 2005;111(15):1954–61.PubMedCrossRef
116.
Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45(3):356–62.PubMedCrossRef
117.
de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension. 2004;43(1):41–7.PubMedCrossRef
118.
Bentley-Lewis R, Adler GK, Perlstein T, Seely EW, Hopkins PN, Williams GH, et al. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab. 2007;92(11):4472–5.PubMedPubMedCentralCrossRef
119.
Schinner S, Willenberg HS, Krause D, Schott M, Lamounier-Zepter V, Krug AW, et al. Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway. Int J Obes. 2007;31(5):864–70.
120.
Bender SB, McGraw AP, Jaffe IZ, Sowers JR. Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? Diabetes. 2013;62(2):313–9.PubMedPubMedCentralCrossRef
121.
Chalupsky K, Cai H. Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 2005;102(25):9056–61.
122.
Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L, Labat C, Benjamin L, Farman N, et al. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J. 2010;24(7):2454–63.
123.
McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med. 2012;18(9):1429–33.PubMedPubMedCentralCrossRef
124.
Gonzalez-Villalobos RA, Janjoulia T, Fletcher NK, Giani JF, Nguyen MT, Riquier-Brison AD, et al. The absence of intrarenal ACE protects against hypertension. J Clin Invest. 2013;123(5):2011–23.PubMedPubMedCentralCrossRef
125.
Ortlepp JR, Breuer J, Eitner F, Kluge K, Kluge R, Floege J, et al. Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia. Eur J Pharmacol. 2002;436(1–2):145–50.PubMedCrossRef
126.
Reisin E, Weir MR, Falkner B, Hutchinson HG, Anzalone DA, Tuck ML. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension. 1997;30(1 Pt 1):140–5.PubMedCrossRef
Metadaten
Titel
Molecular Mechanisms of Sodium-Sensitive Hypertension in the Metabolic Syndrome
verfasst von
Jonathan M. Nizar
Vivek Bhalla
Publikationsdatum
01.08.2017
Verlag
Springer US
Erschienen in
Current Hypertension Reports / Ausgabe 8/2017
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-017-0759-5

Weitere Artikel der Ausgabe 8/2017

Current Hypertension Reports 8/2017 Zur Ausgabe

Antihypertensive Agents: Mechanisms of Drug Action (ME Ernst, Section Editor)

Pathophysiology and Current Clinical Management of Preeclampsia

Letter to the Editor

Comments on: Cernes, R. & Zimlichman, R. Role of Paced Breathing for Treatment of Hypertension. Curr Hypertens Rep (2017) 19: 45

Hypertension and the Heart (D Kitzman and B Upadhya, Section Editors)

Managing Hypertension in the Elderly: What is Different, What is the Same?

Hypertension and Metabolic Syndrome (J Sperati, Section Editor)

Endoplasmic Reticulum Stress, a Driver or an Innocent Bystander in Endothelial Dysfunction Associated with Hypertension?

Blood Pressure Monitoring and Management (J Cockcroft, Section Editor)

The Elusive Search for Optimal Blood Pressure Targets

Letter to the Editor

Response to the Letter from Landman et al:

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise